Compare Davita Inc (DVA) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs CarMax, Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while CarMax, Inc trades at $53.88 (market cap $7.64B). The key difference: Davita Inc is the larger of the two by market cap, and CarMax, Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and CarMax, Inc for 49 Days on average.
| DVA | KMX | |
|---|---|---|
Market Cap | $11.29B | $7.64B |
Volume | 582,204 | 3,610,116 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $64.22 |
52-Week Low | $103.87 | $30.88 |
Typical Hold Time | 113 Days | 49 Days |
Enterprise Value | $24.01B | $25.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
CarMax (KMX) trades at $53.28, down 3.64% amid a bearish technical signal, though recent Q2 2027 earnings beat estimates with EPS of $1.16 versus $0.732 expected. The company reported 19.5% revenue growth to $7.9 billion, driven by strong unit sales and cost control. Analyst consensus is mixed with 29.73% buy ratings and a $58.89 price target, while technical indicators show support at $52-$53 and resistance at $54.
The outlook is cautiously optimistic as CarMax's turnaround strategy shows early traction, but high debt levels and thin net margins near 1% pose risks. Near-term catalysts include the November strategic update, though macroeconomic pressures on consumer spending could challenge sustained growth. The stock offers value with a P/S of 0.28, but investors should monitor execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
